Excellent article by @AnujaJaiswalTOI in @timesofindia on the behavioural and psychological impact of GLP-1 medications, and why mood changes during weight-loss therapy need careful monitoring
The cost to Medicare of covering obesity drugs under Part D has been estimated at between $25 billion and $35 billion over 10 years, which could have been a driving factor in the reluctance or unwillingness of major Part D plan sponsors to participate in the BALANCE model as it was originally designed
These studies show that GCK can treat RA in many ways, and it is an effective drug for treating RA
For example, endocrine experts caution that the age-related GH decline might even be protective (theres ongoing debate), and artificially raising hormone levels in someone without deficiency could do more harm than good
Planning meals ahead and practicing mindful eating can lead to healthier decisions
This happens right when cells need NAD+ most for repairs